BIIB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Biogen Inc. (BIIB) is not a strong buy at the moment for a beginner investor with a long-term focus. While there are some positive developments, such as the licensing deal with Alteogen and stable technical indicators, the company's recent financial performance and insider selling trends raise concerns. It is advisable to hold off on making a purchase until there is clearer evidence of revenue growth or improved financial stability.
The technical indicators for BIIB are mixed. The MACD is positive and expanding, suggesting a bullish momentum. The RSI is neutral at 69.866, and moving averages are converging, indicating no strong directional trend. The stock is trading near its resistance level of 190.268, with support at 181.142.
Biogen's licensing deal with Alteogen for subcutaneous biologics development, including Hybromyze™, is a significant positive catalyst.
Strong patient reliance on LEQEMBI, as indicated by the Phase III Clarity AD study.
Analysts have raised price targets, with some maintaining Buy or Outperform ratings.
Insiders have significantly increased their selling activity, with a rise of 864.10% in the last month.
The company's financial performance in Q4 2025 showed a revenue decline of -7.14% YoY, a net income loss of -$48.9 million, and a negative EPS of -0.
Concerns remain about the company's forward revenue growth trajectory, as highlighted by analysts.
In Q4 2025, Biogen reported a revenue decline of -7.14% YoY to $2.28 billion. Net income dropped to -$48.9 million, a decrease of -118.34% YoY. EPS fell to -0.33, down -118.03% YoY. Gross margin remained stable at 72.46%, down slightly by -0.08% YoY. The financials indicate challenges in revenue growth and profitability.
Analyst sentiment is mixed. While some firms, such as Mizuho, RBC Capital, and H.C. Wainwright, have raised price targets and maintain Buy or Outperform ratings, others like HSBC and Barclays remain cautious with Reduce or Equal Weight ratings. The average price target ranges from $150 to $236, reflecting uncertainty about the company's growth potential.
